PortfoliosLab logoPortfoliosLab logo
ANRO vs. CVKD
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ANRO vs. CVKD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Alto Neuroscience, Inc (ANRO) and Cadrenal Therapeutics Inc. Common Stock (CVKD). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ANRO achieves a 28.82% return, which is significantly higher than CVKD's -53.10% return.


ANRO

1D
0.84%
1M
8.06%
YTD
28.82%
6M
14.42%
1Y
919.11%
3Y*
5Y*
10Y*

CVKD

1D
-9.14%
1M
-38.73%
YTD
-53.10%
6M
-57.80%
1Y
-74.25%
3Y*
-49.02%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

ANRO vs. CVKD - Yearly Performance Comparison


2026 (YTD)20252024
ANRO
Alto Neuroscience, Inc
28.82%320.80%-80.77%
CVKD
Cadrenal Therapeutics Inc. Common Stock
-53.10%-53.21%-31.49%

Correlation

The correlation between ANRO and CVKD is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.18

Correlation (All Time)
Calculated using the full available price history since Feb 2, 2024

0.15

Fundamentals

Market Cap

ANRO:

$754.24M

CVKD:

$6.34M

EPS

ANRO:

-$2.50

CVKD:

-$5.10

PB Ratio

ANRO:

3.10

CVKD:

2.31

Total Revenue (TTM)

ANRO:

$0.00

CVKD:

$0.00

Gross Profit (TTM)

ANRO:

-$421.00K

CVKD:

-$5.92K

EBITDA (TTM)

ANRO:

-$74.36M

CVKD:

-$13.32M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ANRO vs. CVKD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ANRO
ANRO Risk / Return Rank: 9999
Overall Rank
ANRO Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
ANRO Sortino Ratio Rank: 9898
Sortino Ratio Rank
ANRO Omega Ratio Rank: 9898
Omega Ratio Rank
ANRO Calmar Ratio Rank: 100100
Calmar Ratio Rank
ANRO Martin Ratio Rank: 100100
Martin Ratio Rank

CVKD
CVKD Risk / Return Rank: 77
Overall Rank
CVKD Sharpe Ratio Rank: 1111
Sharpe Ratio Rank
CVKD Sortino Ratio Rank: 88
Sortino Ratio Rank
CVKD Omega Ratio Rank: 1111
Omega Ratio Rank
CVKD Calmar Ratio Rank: 44
Calmar Ratio Rank
CVKD Martin Ratio Rank: 22
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ANRO vs. CVKD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Alto Neuroscience, Inc (ANRO) and Cadrenal Therapeutics Inc. Common Stock (CVKD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ANROCVKDDifference
Sharpe ratioReturn per unit of total volatility

+7.97

Sortino ratioReturn per unit of downside risk

+6.90

Omega ratioGain probability vs. loss probability

1.72

0.86

+0.86

Calmar ratioReturn relative to maximum drawdown

27.15

-0.95

+28.10

Martin ratioReturn relative to average drawdown

70.91

-1.75

+72.66

ANRO vs. CVKD - Sharpe Ratio Comparison

The current ANRO Sharpe Ratio is 7.23, which is higher than the CVKD Sharpe Ratio of -0.74. The chart below compares the historical Sharpe Ratios of ANRO and CVKD, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ANRO vs. CVKD - Drawdown Comparison

The maximum ANRO drawdown since its inception was -91.82%, roughly equal to the maximum CVKD drawdown of -96.45%. Use the drawdown chart below to compare losses from any high point for ANRO and CVKD.


Loading charts...

Drawdown Indicators


ANROCVKDDifference

Max Drawdown

Largest peak-to-trough decline

-91.82%

-96.45%

+4.63%

Max Drawdown (1Y)

Largest decline over 1 year

-34.20%

-78.59%

+44.39%

Max Drawdown (3Y)

Largest decline over 3 years

-90.99%

Current Drawdown

Current decline from peak

-17.28%

-96.29%

+79.01%

Average Drawdown

Average peak-to-trough decline

-53.30%

-84.77%

+31.47%

Ulcer Index

Depth and duration of drawdowns from previous peaks

13.07%

42.39%

-29.32%

Volatility

ANRO vs. CVKD - Volatility Comparison

The current volatility for Alto Neuroscience, Inc (ANRO) is 24.19%, while Cadrenal Therapeutics Inc. Common Stock (CVKD) has a volatility of 26.09%. This indicates that ANRO experiences smaller price fluctuations and is considered to be less risky than CVKD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ANROCVKDDifference

Volatility (1M)

Calculated over the trailing 1-month period

24.19%

26.09%

-1.90%

Volatility (6M)

Calculated over the trailing 6-month period

54.92%

68.56%

-13.64%

Volatility (1Y)

Calculated over the trailing 1-year period

128.77%

100.24%

+28.53%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

115.37%

102.28%

+13.09%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

115.37%

102.28%

+13.09%

Dividends

ANRO vs. CVKD - Dividend Comparison

Neither ANRO nor CVKD has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ANRO vs. CVKD - Financials Comparison

This section allows you to compare key financial metrics between Alto Neuroscience, Inc and Cadrenal Therapeutics Inc. Common Stock. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober202600
(ANRO) Total Revenue
(CVKD) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ANRO and CVKD have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CVKD has higher volatility (26.09%) compared to ANRO (24.19%). In terms of maximum drawdown, ANRO dropped -91.82% vs CVKD's -96.45%.

ANRO currently has the higher Sharpe Ratio (7.23 vs -0.74), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ANRO and CVKD

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer